2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: Comment on the article by Buckley et al

We have read the recently published 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (1), and applaud the committee's efforts, but have a number of areas of disagreement. Our main concern is that in adults at high risk for fracture, oral and then parenteral bisphosphonates are recommended over teriparatide in selecting drug therapy. This represents a departure from the 2010 ACR GIO Guidelines (2) which avoided rating bisphosphonates (either oral or parenteral) preferentially over teriparatide. This article is protected by copyright. All rights reserved.